Scinopharm TaiwanTPE:1789 -2.68%76 FCF Margin % is 25.95% as of Dec. 2025, which is 62% above its 10-year median of 16.00. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Scinopharm Taiwan ranks better than 69.31% on this metric.
The historical rank and industry rank for Scinopharm Taiwan's FCF Margin % or its related term are showing as below:
TPE:1789'
s FCF Margin % Range Over the Past 10 Years
Min: -1.68 Med: 16 Max: 31.34
Current: 9.47
During the past 13 years, the highest FCF Margin % of Scinopharm Taiwan was 31.34%. The lowest was -1.68%. And the median was 16.00%.
TPE:1789's FCF Margin % is ranked better than 69.31% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs TPE:1789: 9.47
Scinopharm Taiwan FCF Margin % Related Terms
Scinopharm Taiwan FCF Margin % Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a FCF Margin % of 25.95% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Scinopharm Taiwan and its competitors. This is 62% above median its historical median of 16.00. According to the industry distribution chart, Scinopharm Taiwan ranks #294 out of 958 companies in the Drug Manufacturers industry, placing it in the top 30.7%.
Is Scinopharm Taiwan's FCF Margin % too high?
Scinopharm Taiwan's current FCF Margin % of 25.95% is 62% above median its 10-year median of 16.00. The Drug Manufacturers industry median FCF Margin % is 2.45. Scinopharm Taiwan's value of 25.95% is 961.3% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #294 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #294 out of 958 companies for FCF Margin %. This puts Scinopharm Taiwan in the upper half of its industry. The industry median FCF Margin % is 2.45. Scinopharm Taiwan's value of 25.95% is 961.3% above this benchmark. While the company's 10-year median is 16.00 vs. the industry median of 2.45, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current FCF Margin % of 25.95% is 961.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current FCF Margin % is 25.95%, which is 62% above median its own 10-year median of 16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.00 — trading 26% below its estimated fair value. The current FCF Margin % is 25.95%, which is 62% above median its 10-year median of 16.00 and 961.3% above the Drug Manufacturers industry median of 2.45. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current FCF Margin % is 25.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.00 is trading 26% below its estimated GF Value™ of NT$27.02.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
FCF Margin %: 25.95% (62% above median its 10-year median of 16.00)
GF Value™: NT$27.02 vs. price of NT$20.00 (26% below fair value)
Industry Position: 961.3% above the Drug Manufacturers median (#294 of 958)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
